Re: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

被引：0
作者：
Chang, Sam S.
机构：
来源：
JOURNAL OF UROLOGY | 2022年 / 207卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：228 / 228
页数：1
相关论文
共 50 条
  • [21] Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis
    Zhu, Youwen
    Liu, Kun
    Zhu, Hong
    Li, Shan
    Yuan, Dan
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
  • [22] Clinical significance of the dose modification of enfortumab vedotin monotherapy for advanced urothelial carcinoma
    Minato, Akinori
    Takaba, Tomohisa
    Sugita, Yoshihiro
    Kaneko, Yuya
    Hongyo, Ryota
    Tanaka, Toshinobu
    Bando, Taro
    Sugi, Takaomi
    Mizushima, Yui
    Matsukawa, Takuo
    Jojima, Kazumasa
    Higashijima, Katsuyoshi
    Nagata, Yujiro
    Tomisaki, Ikko
    Kashiwagi, Eiji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2025,
  • [23] Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
    Powles, T.
    Valderrama, B. P.
    Gupta, S.
    Bedke, J.
    Kikuchi, E.
    Hoffman-Censits, J.
    Iyer, G.
    Vulsteke, C.
    Park, S. H.
    Shin, S. J.
    Castellano, D.
    Fornarini, G.
    Li, J. R.
    Guemues, M.
    Mar, N.
    Loriot, Y.
    Flechon, A.
    Duran, I
    Drakaki, A.
    Narayanan, S.
    Yu, X.
    Gorla, S.
    Moreno, B. Homet
    van der Heijden, M. S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (10) : 875 - 888
  • [24] Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
    Maiorano, Brigida Anna
    Catalano, Martina
    Maiello, Evaristo
    Roviello, Giandomenico
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [25] Enfortumab Vedotin for Elderly Advanced Urothelial Carcinoma Patients or Those With a Poor Performance Status
    Furubayashi, Nobuki
    Minato, Akinori
    Tomoda, Toshihisa
    Masaoka, Hiroyuki
    Hori, Yoshifumi
    Kiyoshima, Keijiro
    Negishi, Takahito
    Haraguchi, Yusuke
    Koga, Toshiki
    Song, Yoohyun
    Harada, Kenichi
    Kuroiwa, Kentaro
    Seki, Narihito
    Fujimoto, Naohiro
    Nakamura, Motonobu
    ANTICANCER RESEARCH, 2024, 44 (08) : 3409 - 3417
  • [26] Salvage Surgery Following Remarkable Tumor Shrinkage With Enfortumab Vedotin in Advanced Urothelial Carcinoma
    Minami, Keita
    Narimatsu, Rei
    Sasaki, Hajime
    Tanabe, Tatsu
    Tanaka, Hiroshi
    IJU CASE REPORTS, 2025, 8 (03) : 257 - 260
  • [27] Efficacy and safety of routine corticosteroid premedication in enfortumab vedotin therapy for advanced urothelial carcinoma
    Hara, Takuto
    Suzuki, Kotaro
    Tobe, Taisuke
    Ueki, Hideto
    Wakita, Naoto
    Okamura, Yasuyoshi
    Bando, Yukari
    Terakawa, Tomoaki
    Hyodo, Yoji
    Chiba, Koji
    Teishima, Jun
    Yao, Akihisa
    Miyake, Hideaki
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2025,
  • [28] Steroid Premedication Impact on Efficacy and Cutaneous Toxicity of Enfortumab Vedotin for Advanced Urothelial Carcinoma
    Furubayashi, Nobuki
    Mochida, Manabu
    Kijima, Atsuhiro
    Fujimoto, Yushi
    Nakamura, Motonobu
    Negishi, Takahito
    IN VIVO, 2025, 39 (03): : 1607 - 1614
  • [29] Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date
    Moussa, Mohamad
    Papatsoris, Athanasios
    Abou Chakra, Mohamed
    Dellis, Athanasios
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 453 - 462
  • [30] Enfortumab Vedotin in urothelial cancer
    Alt, Marie
    Stecca, Carlos
    Tobin, Swanee
    Jiang, Di Maria
    Sridhar, Srikala S.
    THERAPEUTIC ADVANCES IN UROLOGY, 2020, 12
12345